Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Endroit courant :
> This Story

Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Send us your Comments




More Industry Headlines

Peeling back the Medicare Advantage onion Understanding the high growth rate of MA plan coverage

FDA finds duodenoscope contamination risk still too high Up to 5.4 percent of properly collected samples has 'high concern' organisms

Israeli researchers develop first 3D heart from patient's biological materials A first — complete with blood vessels, ventricles and cells

Air medical transportation: How a 15-minute ride may cost $30,000, and how we can change it Reducing sky-high transport expenses

Using comic illustrations to support patient understanding of cardiac catheterization Making patients more satisfied, less anxious and more informed

X-ray sheds new light on ancient mummy The Everhart Museum in PA tapped Geisinger Radiology for help

Breaking barriers in Alzheimer’s disease with focused ultrasound Researchers at Sunnybrook in Toronto are closing the therapeutic gap

HHS releases second draft of TEFCA for nationwide interoperability Requirements for sharing electronic health information

Improving surgical outcomes by imaging head and neck tumors in real time Researchers use tech developed by Perimeter Medical Imaging

Future-ready medical devices - Answering the current and future needs of patients and users

Endologix confident
in its position

Endologix nie l'infraction au brevet de périphérique de barde

par Astrid Fiano , DOTmed News Writer
Endologix, Inc.(Endologix) of Irvine, Calif., has issued a statement disputing allegations of patent infringement in a federal complaint filed by Bard Peripheral Vascular, Inc. (Bard). Bard, of Tempe, Ariz., filed suit in U.S. District Court, District of Arizona alleging that Endologix's expanded polytetrafluoroethylene (ePTFE) prosthetic vascular graft material in its Powerlink® system infringed Bard's "Prosthetic Vascular Graft" patent (the '135 patent). Bard develops vascular, urology, oncology and surgical specialty products. Endologix develops technologies for vascular diseases.

Bard filed the suit earlier in August. Atrium Medical Corp. (Atrium) of Hudson, NH, is also named as a defendant. In the complaint, Bard alleges that Atrium has infringed upon the '135 patent through its products using ePTFE prosthetic vascular grafts including its Advanta™ VS PTFE Vascular Graft, Advanta™ SST PTFE Vascular Graft, and Advanta™ VXT PTFE Vascular Graft.

Story Continues Below Advertisement

RaySafe helps you avoid unnecessary radiation

RaySafe solutions are designed to minimize the need for user interaction, bringing unprecedented simplicity & usability to the X-ray room. We're committed to establishing a radiation safety culture wherever technicians & medical staff encounter radiation.

The Endologix statement says the company is "confident" that it has not infringed upon the patent, and will vigorously defend its position. John McDermott, President and Chief Executive Officer of Endologix said: "We are well versed on the patent cited in the lawsuit. Based on significant prior evaluations, testing and outside legal reviews, we are confident in our belief that we do not infringe the patent. Before developing and manufacturing our own in-house ePTFE graft material, we conducted a deep and thorough review of the patent landscape to insure that we would not infringe on any existing intellectual property. This included a specific, rigorous review of the Bard Peripheral patent named in the lawsuit, both internally and by outside legal counsel. Based upon those reviews, we believe the alleged infringement claims are without merit and intend to vigorously defend our position."

Bard is asking for damages and an injunction against Atrium and Endologix from selling the alleged infringing products. Endologix says it received FDA approval to manufacture its ePTFE graft material in April 2007 and has manufactured all of its own graft material since 2008.

Adapted in part from an Endologix press release, available here.


Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2019 DOTmed.com, Inc.